Swiss National Bank’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-215,800
Closed -$15.6M 2341
2025
Q4
$15.6M Buy
215,800
+7,000
+3% +$452K 0.01% 756
2025
Q3
$9.1M Buy
208,800
+36,600
+21% +$1.48M 0.01% 1012
2025
Q2
$4.89M Buy
172,200
+10,300
+6% +$307K ﹤0.01% 1314
2025
Q1
$4.78M Sell
161,900
-12,500
-7% -$389K ﹤0.01% 1287
2024
Q4
$5.07M Buy
174,400
+18,800
+12% +$786K ﹤0.01% 1324
2024
Q3
$7.15M Sell
155,600
-800
-0.5% -$34.7K ﹤0.01% 1104
2024
Q2
$6.39M Buy
156,400
+15,600
+11% +$448K ﹤0.01% 1126
2024
Q1
$3.59M Buy
140,800
+24,000
+21% +$376K ﹤0.01% 1506
2023
Q4
$1.06M Sell
116,800
-7,700
-6% -$51.5K ﹤0.01% 2215
2023
Q3
$794K Sell
124,500
-6,500
-5% -$56K ﹤0.01% 2369
2023
Q2
$1.45M Buy
131,000
+16,200
+14% +$203K ﹤0.01% 2096
2023
Q1
$1.76M Sell
114,800
-19,600
-15% -$431K ﹤0.01% 1909
2022
Q4
$2.98M Buy
134,400
+45,900
+52% +$684K ﹤0.01% 1642
2022
Q3
$1.45M Buy
88,500
+5,300
+6% +$101K ﹤0.01% 2097
2022
Q2
$1.21M Hold
83,200
﹤0.01% 2259
2022
Q1
$1.54M Buy
83,200
+8,000
+11% +$136K ﹤0.01% 2184
2021
Q4
$1.79M Hold
75,200
﹤0.01% 2139
2021
Q3
$1.85M Buy
75,200
+38,000
+102% +$826K ﹤0.01% 2106
2021
Q2
$919K Buy
37,200
+7,500
+25% +$174K ﹤0.01% 2512
2021
Q1
$648K Hold
29,700
﹤0.01% 2431
2020
Q4
$758K Buy
+29,700
New +$866K ﹤0.01% 2394

Other funds holding RNAM

Swiss National Bank's RNAM Position: Q1 2026 in Review

Swiss National Bank sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 215,800 shares — an estimated $15.6M sold.

Swiss National Bank first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $15.6M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Swiss National Bank reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Swiss National Bank sold 215,800 Avidity Biosciences shares in Q1 2026, an estimated $15.6M.
  • Swiss National Bank first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
  • Swiss National Bank's Avidity Biosciences position peaked at $15.6M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.